Opinion

Video

Unmet Needs and Future Direction in HER2+ Breast Cancer

Author(s):

Joyce A. O'Shaughnessy, MD,Melinda L. Telli, MD

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Video content above is prompted by the following:

  • Please provide your closing thoughts about current and future management in HER2+ early stage mBC and HER2-low and ultra-low mBC.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria
Video

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Related Content
HR+ Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 29th 2025

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

Daniel P. Petrylak, MD, professor, medicine (medical oncology) and urology, chief, Genitourinary Oncology, Yale School of Medicine and Smilow Cancer Hospital
April 24th 2025

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 28th 2025

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 25th 2025

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

Zafar Sayed, MD
April 24th 2025

Deintensification of Treatment Modalities Is Crucial to Consider in Head and Neck Cancer